Novo Nordisk shares fall on weight loss drug trial results – Proactive Investors USA

Novo Nordisk shares fall on weight loss drug trial results  Proactive Investors USA

Novo Nordisk Stock Drops on New Obesity Drug Findings. Eli Lilly Stands to Gain. – Barron’s

Novo Nordisk Stock Drops on New Obesity Drug Findings. Eli Lilly Stands to Gain.  Barron’s

Roche announces hub for cardiovascular, renal and metabolism research

Roche has announced the launch of the Roche Genentech Innovation Center Boston, which will serve as…

Eli Lilly plans launch of weight-loss drug in emerging markets by 2026, CFO says – TradingView

Eli Lilly plans launch of weight-loss drug in emerging markets by 2026, CFO says  TradingView

Novo Nordisk stock sinks on weight loss drug trial letdown – Yahoo Finance

Novo Nordisk stock sinks on weight loss drug trial letdown  Yahoo Finance

Novo Nordisk Shares Sink on Latest CagriSema Weight Loss Drug Study – Investopedia

Novo Nordisk Shares Sink on Latest CagriSema Weight Loss Drug Study  Investopedia

Dr Jack Mosley on ‘gamechanger’ weight loss method to beat ‘food noise’ – Yahoo News UK

Dr Jack Mosley on ‘gamechanger’ weight loss method to beat ‘food noise’  Yahoo News UK

Novo Dips After CagriSema’s Latest Lower-Than-Expected Weight Loss Readout – BioSpace

Novo Dips After CagriSema’s Latest Lower-Than-Expected Weight Loss Readout  BioSpace

Michael Mosley’s son writes book on weight-loss drugs continuing father’s work – The Independent

Michael Mosley’s son writes book on weight-loss drugs continuing father’s work  The Independent

Novo Nordisk’s CagriSema shows nearly 16 percent weight loss – PharmaLive

Novo Nordisk’s CagriSema shows nearly 16 percent weight loss  PharmaLive